GLAXOSMITHKLINE PLC Form 6-K September 12, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 12 September 2018

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')

#### Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms E Walmsley

b) Position/status

Chief Executive Officer

Initial notification/

Initial notification amendment

2. Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each

a) Description of the financial instrument ('Ordinary Shares')

ISIN: GB0009252882

Acquisition of Ordinary Shares under the Company's Share

b) Nature of the transaction Reward Plan.

Price(s) Volume(s)

c) Price(s) and volume(s) £14.9717 8 (partnership shares)

£14.9717 8 (matching shares)

Aggregated information

d)

16 Ordinary Shares

£14.9717

Aggregated volume Price

e) Date of the transaction 2018-09-11

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr R G Connor

b) Position/status President, Global Vaccines

Initial notification/
Initial notification

amendment

Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each

('Ordinary Shares')

ISIN: GB0009252882

**Acquisition of Ordinary Shares** under the Company's Share

b) Nature of the transaction Reward Plan.

> Price(s) Volume(s)

£14.9717 8 (partnership shares) c) Price(s) and volume(s)

£14.9717 8 (matching shares)

Aggregated information

d)

16 Ordinary Shares Aggregated volume Price

£14.9717

e) Date of the transaction 2018-09-11

Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S Dingemans

b) Position/status Chief Financial Officer

Initial notification/ Initial notification

amendment

Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence each

('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

**Acquisition of Ordinary Shares** 

under the Company's Share

Reward Plan.

Price(s) Volume(s)

c) Price(s) and volume(s) £14.9717 8 (partnership shares)

£14.9717 8 (matching shares)

d) Aggregated information

b) Nature of the transaction

Aggregated volume Price

16 Ordinary Shares

£14.9717

e) Date of thetransaction 2018-09-11

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr N Hirons

b) Position/status SVP, Global Ethics & Compliance

Initial notification/

initial notification amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each

('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

Acquisition of Ordinary Shares

under the Company's Share

b) Nature of the transaction Reward Plan.

Price(s) Volume(s)

c) Price(s) and volume(s) £14.9717 8 (partnership shares)

£14.9717 8 (matching shares)

Aggregated information

d) 16 Ordinary Shares

Aggregated volume Price £14.9717

e) Date of the transaction 2018-09-11

Place of the transaction

London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr L Miels

b) Position/status President, Global Pharmaceuticals

Initial notification/
Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793
Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each

('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

Acquisition of Ordinary Shares

under the Company's Share

b) Nature of thetransaction Reward Plan.

Price(s) Volume(s)

c) Price(s) and volume(s) £14.9717 8 (partnership shares)

£14.9717 8 (matching shares)

Aggregated information

d)

Aggregated volume Price 16 Ordinary Shares

£14.9717

e) Date of the transaction 2018-09-11

Place of the transaction

London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Nameb) Position/statusMr D S RedfernChief Strategy Officer

Initial notification/

amendment

Initial notification

2. Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each

('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of thetransaction Acquisition of Ordinary Shares

under the Company's Share

Reward Plan.

Price(s) Volume(s)

c) Price(s) and volume(s) £14.9717 8 (partnership shares)

£14.9717 8 (matching shares)

Aggregated information

d)

16 Ordinary Shares

Aggregated volume Price £14.9717

e) Date of the transaction 2018-09-11

Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

Mr R Simard a) Name

President, Pharmaceutical Supply

b) Position/status Chain

Initial notification/ Initial notification c)

amendment

Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

5493000HZTVUYLO1D793 b) LEI

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence each

('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

**Acquisition of Ordinary Shares** 

under the Company's Share

Reward Plan.

Price(s) Volume(s)

£14.9717 9 (partnership shares) c) Price(s) and volume(s)

£14.9717 9 (matching shares)

Aggregated information

d) Aggregated volume Price

b) Nature of thetransaction

18 Ordinary Shares

£14.9717

e) Date of the transaction 2018-09-11

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms C Thomas

b) Position/status SVP, Human Resources

Initial notification/
Initial notification

amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each

('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

Acquisition of Ordinary Shares

under the Company's Share

Reward Plan.

Price(s) Volume(s)

c) Price(s) and volume(s) £14.9717 8 (partnership shares)

£14.9717 8 (matching shares)

Aggregated information

b) Nature of thetransaction

d) 16 Ordinary Shares

Aggregated volume Price £14.9717

e) Date of the transaction 2018-09-11

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr P C Thomson

b) Position/status President, Global Affairs

c) Initial notification/ amendment Initial notification

Details of the issuer, emission allowance market participant, auction

<sup>2</sup>. platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each

('Ordinary Shares')
ISIN: GB0009252882

a) Description of the financial instrument

Acquisition of Ordinary Shares

b) Nature of the transaction under the Company's Share

Reward Plan.

Price(s) Volume(s)

c) Price(s) and volume(s) £14.9717 8 (partnership shares)

£14.9717 8 (matching shares)

Aggregated information

d)
Aggregated volume Price

16 Ordinary Shares

£14.9717

e) Date of thetransaction 2018-09-11

Place of the transaction

London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Nameb) Position/statusMrs V A WhyteCompany Secretary

c) Initial notification/ Initial notification

Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each

('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares

under the Company's Share

Reward Plan.

Price(s) Volume(s)

c) Price(s) and volume(s) £14.9717 8 (partnership shares)

£14.9717 8 (matching shares)

Aggregated information

d)

16 Ordinary Shares

Aggregated volume Price £14.9717

e) Date of thetransaction

2018-09-11

Place of the transaction

London Stock Exchange (XLON)

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 $GlaxoSmithKline\ plc$ 

(Registrant)

Date: September 12, 2018

By: VICTORIA WHYTE

-----

Victoria Whyte

Authorised Signatory for and on behalf of GlaxoSmithKline plc